Hilton Santa Fe Historic Plaza Hotel Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2002



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Strategies for the Identification and Development of Novel Antimicrobial Agents (B1)


Organizer(s) Steven J. Projan, Karen Bush and Richard J. Whitley
January 31—February 5, 2002
Hilton Santa Fe Historic Plaza Hotel • Santa Fe, New Mexico USA
Abstract Deadline: Oct 8, 2001
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Nov 30, 2001

Sponsored by GlaxoSmithKline

Summary of Meeting:
In many ways we are entering the golden age of anti-infective research. Many of the major pathogenic bacteria have been completely sequenced and complete sequence information is also available for most all clinically important viruses and some pathogenic fungi. While the roles of many bacterial and viral genes have yet to be elucidated, a variety of methods including proteomics, transcriptional profiling, in vivo expression technology and tightly regulable, in vivo gene expression are giving us new insights into the physiology of infections at the level of both the pathogen and the host. As multitudes of potential targets have emerged from these and other studies, an increasing array of methods for finding substances that interact with these novel (and not so novel) targets have also been developed and are being improved upon daily. These technologies are making increasingly effective uses of automated approaches to screening and chemical syntheses, structural biology approaches to rational drug design and ever-sophisticated animal models of human disease. Perhaps our greatest difficulty is being able to effectively utilize the vast amount of biological data being generated in the drug discovery process. The goal of this conference will be to interface our new understanding of molecular pathogenesis with our enhanced ability to define targets and screen for novel molecules that interact with those targets. While there are many levels at which one can affect the course of infection from prevention through therapy, this conference will focus on developing treatments for infected patients. However we will also try and focus not only on direct interference with bacterial or viral replication but also on strategies to boost host defenses as a means of therapy, clearly an under-appreciated subject. Tempering this enthusiasm is the understanding that resistance to anti-infective agents is the direct consequence of their use, but our ever improving understanding of both pathogenesis and resistance may allow for counter-strategies to prevent or at least ameliorate, the acquisition and spread of resistant pathogens. While it is becoming increasingly uncommon to combine anti-viral and anti-bacterial drug discovery symposia, the fact is that the rapid development of resistance to both antibacterial and antiviral agents, the molecular nature of the targets, and the approaches to find molecules that interact with them are actually converging. This meeting will provide an excellent opportunity for cross-fertilization.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


THURSDAY, JANUARY 31

16:00—19:00
Registration

Promenade
18:15—19:15
Welcome

Promenade
19:15—19:30
Orientation

Mesa Ballroom A-B
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom A-B
* Richard J. Whitley, Children's Hospital, USA

Barbara E. Murray, University of Texas-Houston Medical School, USA
New Anti-Infective Drugs - What Do We Need and When are We Going to Need Them?


FRIDAY, FEBRUARY 1

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Platform Technologies - Give Us a Robot, a Place to Stand, and We Can Screen a World of Compounds, but Will We Find Anything? Session Sponsored by Infection Discovery - AstraZeneca R&D, Boston.
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom A-B
* Karen Bush, Indiana University, USA

Chaitan Khosla, Stanford University, USA
Challenges and Opportunities in Developing Natural Product Antimicrobial Agents

Richard J. White, Versicor Inc., USA
Using Combinatorial Chemistry to Find New Drugs, New Targets or Pump Life into Old Ones

Manuel A. Navia, eXlthera Pharmaceuticals, USA
The First Wave of Drugs from Structure-Based Drug Design

David Knowles, RiboTargets, UK
Virtual Screening, Better than the Real Thing? Lessons from the Bacterial Ribosome

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Mesa Ballroom C
13:00—22:00
Poster Viewing

Mesa Ballroom C
16:30—17:00
Coffee & Snacks Available

Promenade
17:00—19:00
Genomics & Bioinformatics: A Promise Fulfilled or an Expensive Hobby?
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom A-B
* Steven J. Projan, MedImmune, USA

George M. Weinstock, The Jackson Laboratory, USA
Microbial Genomics: Fact and Fancy

Karen Joy Shaw, Johnson & Johnson Pharmaceutical Research & Development, LLC, USA
Antibacterial Drug Discovery and DNA Microarrays

Klaus Früh, Oregon Health & Science University, USA
Uncovering Novel Targets for Antiviral Therapy by Functional Genomics

19:00—20:00
Welcome Mixer

Promenade
20:00—22:00
Poster Session 1

Mesa Ballroom C

SATURDAY, FEBRUARY 2

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Novel and Not So Novel Targets - Can't Anybody Here Shoot Straight?
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom A-B
* Karen Bush, Indiana University, USA

Jeffrey W. Jacobs, Ardelyx, USA
Targeting Protein-Protein Interactions - A Fragment Assembly Approach

Scott Hultgren, Washington University School of Medicine, USA
Pilicides

Clayton C. Huntley, National Institutes of Health, USA
In Vitro Analysis of Resistance to RFI-641, a Novel RSV Fusion Inhibitor

Philip J. Youngman, Elitra Pharmaceuticals, USA
Novel Targets vs. Novel Ways to Exploit Well-Validated Target Pathways

09:20—09:40
Coffee Break

Promenade
16:30—17:00
Coffee & Snacks Available

Promenade
17:00—19:00
Taking on Resistance: A Losing Battle or a Winning Strategem?
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom A-B
* Richard J. Whitley, Children's Hospital, USA

Karen Bush, Indiana University, USA
Beta-Lactamase Inhibitors: The Bacteria Strike Back. How Should We Respond?

Olga Lomovskaya, Medicine Company, USA
So Many Pumps, So Few Drugs

David C. Hooper, Massachusetts General Hospital, USA
Are Drug-Resistant Organisms Less Virulent?

19:00—20:00
Welcome Mixer

Promenade

SUNDAY, FEBRUARY 3

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Antiviral Chemotherapeutics - The Good, the Bad and the Ugly. Session Sponsored by Eli Lilly and Company, Lilly Research Laboratories.
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom A-B
* Richard J. Whitley, Children's Hospital, USA

Bernard Roizman, University of Chicago, USA
Novel Targets for Anti Herpes Simplex Virus Therapy

Marc S. Collett, Viropharma, Inc., USA
Do We Need a Rhinovirus Inhibitor? Is There Such a Thing? If So, Does it Work?

Charles M. Rice, Rockefeller University, USA
Hepatitis C - How can a Virus that Replicates so Poorly Make so Many People Sick?

Richard P. Novick, New York University, USA
Targeting the Regulation of Staphylococcal Virulence. Can this Work for Other Organisms?

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Mesa Ballroom C
13:00—22:00
Poster Viewing

Mesa Ballroom C
16:30—17:00
Coffee & Snacks Available

Promenade
17:00—19:00
Virulence, Regulation and the Molecular Physiology of Infection: Is There Hope Amid the Hype?
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom A-B
* Steven J. Projan, MedImmune, USA

Peter M. Palese, Icahn School of Medicine at Mount Sinai, USA
Toward a Better Understanding of the Intracellular Trafficking of Influenza Virus Components: Novel Antiviral Targets?

James A. Hoch, The Scripps Research Institute, USA
Virulence- and Antibiotic Resistance-Associated Two-Component Signal Transduction Systems as Targets for Antimicrobial Therapy

Thomas E. Shenk, Princeton University, USA
Human Cytomegalovirus Blocks the Induction of a Set of Cellular Anti-Viral Genes

19:00—20:00
Welcome Mixer

Promenade
20:00—22:00
Poster Session 2

Mesa Ballroom C

MONDAY, FEBRUARY 4

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Lessons from Immunology?
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom A-B
* Steven J. Projan, MedImmune, USA

Arturo Casadevall, Albert Einstein College of Medicine, USA
New Insights into Antibody-Structure Function

Ferric C. Fang, University of Washington School of Medicine, USA
Can We Treat Infectious Diseases by Modulating Host Defenses?

Michael R. Yeaman, University of California, Los Angeles, USA
Code Among Chaos: Lessons from Host Defense Proteins

Zimra R. Israel, Wyeth Pharmaceuticals, USA
Immunotherapeutic Vaccines for HIV

09:20—09:40
Coffee Break

Promenade
16:30—17:00
Coffee & Snacks Available

Promenade
17:00—19:00
General Strategies/Specific Solutions
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom A-B
* Karen Bush, Indiana University, USA

Trevor J. Trust, AstraZeneca R&D Boston, USA
Broad Spectrum vs. Pathogen Specific Antimicrobials - The Case for Helicobacter pylori Inhibitors

Lynn L. Silver, LL Silver Consulting, USA
Choose Your Weapons: Pathway Screening vs. Identification of Single Enzyme Inhibitors

Jianshi Tao, Novartis, USA
Blocking Target Function with Inducibly Expressed Peptides: Application to Antibacterial Drug Discovery

19:00—20:00
Welcome Mixer

Promenade/Mesa C
20:00—23:00
Entertainment

Mesa C

TUESDAY, FEBRUARY 5

 
Departure


*Session Chair †Invited, not yet responded.



We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676